Insider transactions

EDGAR

ANAPTYSBIO, INC.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-21.

Open-market purchases (code P)
3 transactions, 374,580 shares
Sum of shares × price per share: 17,224,592.7798
Open-market sales (code S)
42 transactions, 199,604 shares
Sum of shares × price per share: 9,752,105.1802

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–50 of 191

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-11-18 Filed 2026-11-18EcoR1 Capital, LLC Director · 10% ownerNODELMAN OLEG Director · 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)138,09346.5419
6,427,110.5967

Derived: shares × price per share. Exact value 6427110.5967.

8,254,674Indirect (I) See NoteNo
F5, F6, F1
  • F5 Qualified Fund purchased 127,917 of the shares in this transaction.
  • F6 After this transaction, Qualified Fund held 7,642,937 shares of the Issuer's Common Stock.
  • F1 The reporting persons are EcoR1 Capital, LLC (EcoR1), Oleg Nodelman and EcoR1 Capital Fund Qualified L.P. (Qualified Fund). EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund (collectively, the Funds). Mr. Nodelman is the manager and controlling owner of EcoR1 and a director of the Issuer. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein.
Open filing 0000935836-26-000631 Read from the filing’s XML Dispute this row
2026-11-17 Filed 2026-11-18EcoR1 Capital, LLC Director · 10% ownerNODELMAN OLEG Director · 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)152,36745.6553
6,956,361.0951

Derived: shares × price per share. Exact value 6956361.0951.

8,116,581Indirect (I) See NoteNo
F3, F4, F1
  • F3 Qualified Fund purchased 113,048 of the shares in this transaction.
  • F4 After this transaction, Qualified Fund held 7,515,020 shares of the Issuer's Common Stock
  • F1 The reporting persons are EcoR1 Capital, LLC (EcoR1), Oleg Nodelman and EcoR1 Capital Fund Qualified L.P. (Qualified Fund). EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund (collectively, the Funds). Mr. Nodelman is the manager and controlling owner of EcoR1 and a director of the Issuer. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein.
Open filing 0000935836-26-000631 Read from the filing’s XML Dispute this row
2026-11-16 Filed 2026-11-18EcoR1 Capital, LLC Director · 10% ownerNODELMAN OLEG Director · 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)84,12045.6624
3,841,121.088

Derived: shares × price per share. Exact value 3841121.0880.

7,964,214Indirect (I) See NoteNo
F2, F1
  • F2 Qualified Funds did not purchase any of the securities in this transaction.
  • F1 The reporting persons are EcoR1 Capital, LLC (EcoR1), Oleg Nodelman and EcoR1 Capital Fund Qualified L.P. (Qualified Fund). EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund (collectively, the Funds). Mr. Nodelman is the manager and controlling owner of EcoR1 and a director of the Issuer. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein.
Open filing 0000935836-26-000631 Read from the filing’s XML Dispute this row
2026-10-01 Filed 2026-10-02RENTON HOLLINGS Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)5,00018.03
90,150

Derived: shares × price per share. Exact value 90150.00.

15,995Direct (D) Yes— Open filing 0001187333-26-000004 Read from the filing’s XML Dispute this row
2026-10-01 Filed 2026-10-02RENTON HOLLINGS Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)5,00049.8743
249,371.5

Derived: shares × price per share. Exact value 249371.5000.

10,995Direct (D) Yes
F1, F2
  • F1 The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026.
  • F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.435 to $50.37 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001187333-26-000004 Read from the filing’s XML Dispute this row
2026-10-01 Filed 2026-10-02RENTON HOLLINGS Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Common Stock — underlying Common Stock (5,000) — exercise price 18.03
Disposed (D)5,0000—10,000Direct (D) Yes
F3, F4
  • F3 The stock option is fully vested and exercisable.
  • F4 In addition to the remaining options to purchase 10,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 92,320 shares of common stock, which options vest according to their terms.
Open filing 0001187333-26-000004 Read from the filing’s XML Dispute this row
2026-09-15 Filed 2026-09-17Orwin John A Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)1,3000—17,995Direct (D) No
F1
  • F1 Each restricted stock award (RSU) represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
Open filing 0001477384-26-000013 Read from the filing’s XML Dispute this row
2026-09-15 Filed 2026-09-17Orwin John A Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Unit — underlying Common Stock (1,300)
Disposed (D)1,3000—0Direct (D) No
F1, F2
  • F1 Each restricted stock award (RSU) represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
  • F2 The RSUs shall vest as to 1/3 of the total shares on September 15, 2024, and thereafter vests as to 1/3 of the total RSUs on September 15, 2025; and as to 1/3 of the total RSUs on September 15, 2026, subject to the provision of services to the Company on each vesting date.
Open filing 0001477384-26-000013 Read from the filing’s XML Dispute this row
2026-06-15 Filed 2026-06-17Schmid John P. Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)6,0300—37,652Direct (D) No
F1
  • F1 Each restricted stock award (RSU) represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
Open filing 0001478916-26-000011 Read from the filing’s XML Dispute this row
2026-06-15 Filed 2026-06-17Schmid John P. Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Unit — underlying Common Stock (6,030)
Disposed (D)6,0300—0Direct (D) No
F1, F2
  • F1 Each restricted stock award (RSU) represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
  • F2 The RSUs vests as to 100% of the total RSUs on June 15, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Open filing 0001478916-26-000011 Read from the filing’s XML Dispute this row
2026-06-15 Filed 2026-06-17Orwin John A Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)6,0300—16,695Direct (D) No
F1
  • F1 Each restricted stock award (RSU) represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
Open filing 0001477384-26-000010 Read from the filing’s XML Dispute this row
2026-06-15 Filed 2026-06-17Orwin John A Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Unit — underlying Common Stock (6,030)
Disposed (D)6,0300—0Direct (D) No
F1, F2
  • F1 Each restricted stock award (RSU) represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
  • F2 The RSUs vests as to 100% of the total RSUs on June 15, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Open filing 0001477384-26-000010 Read from the filing’s XML Dispute this row
2026-06-15 Filed 2026-06-17RENTON HOLLINGS Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)6,0300—10,995Direct (D) No
F1
  • F1 Each restricted stock award (RSU) represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
Open filing 0001187333-26-000003 Read from the filing’s XML Dispute this row
2026-06-15 Filed 2026-06-17RENTON HOLLINGS Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Unit — underlying Common Stock (6,030)
Disposed (D)6,0300—0Direct (D) No
F1, F2
  • F1 Each restricted stock award (RSU) represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
  • F2 The RSUs vests as to 100% of the total RSUs on June 15, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Open filing 0001187333-26-000003 Read from the filing’s XML Dispute this row
2026-05-11 Filed 2026-05-13Hughes Owen Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (11,250)
Acquired (A)11,2500—11,250Direct (D) No
F1, F2
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
  • F2 1/3 of the RSUs shall vest on May 11, 2027 and 1/3 of the RSUs shall vest in equal annual installments until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Open filing 0001575933-26-000002 Read from the filing’s XML Dispute this row
2026-05-11 Filed 2026-05-13Murphy Christopher M. Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (25,765)
Acquired (A)25,7650—25,765Direct (D) No
F1, F2
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
  • F2 The RSUs vests as to 25% of the total RSUs annually commencing on May 11, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Open filing 0002005986-26-000002 Read from the filing’s XML Dispute this row
2026-04-27 Filed 2026-04-29GRAY SUSANNAH Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Unit — underlying Common Stock (11,250)
Acquired (A)11,2500—11,250Direct (D) No
F1, F2
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
  • F2 1/3 of the RSUs shall vest on April 27, 2027 and 1/3 of the RSUs shall vest in equal annual installments until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Open filing 0001833453-26-000003 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-23Faga Daniel Director · Officer: President, CEO
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (11,000) — exercise price 31.12
Disposed (D)11,0000—11,000Direct (D) No
F1
  • F1 The stock option is fully vested and exercisable.
Open filing 0001673528-26-000012 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-22RENTON HOLLINGS Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (15,000) — exercise price 24.60
Disposed (D)15,0000—15,000Direct (D) No
F1, F2
  • F1 Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the Separation Agreement), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement.
  • F2 The stock option is fully vested and exercisable.
Open filing 0001187333-26-000002 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-22RENTON HOLLINGS Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (15,000) — exercise price 18.03
Acquired (A)15,0000—15,000Direct (D) No
F1, F2
  • F1 Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the Separation Agreement), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement.
  • F2 The stock option is fully vested and exercisable.
Open filing 0001187333-26-000002 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-22RENTON HOLLINGS Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (6,000) — exercise price 104.81
Disposed (D)6,0000—6,000Direct (D) No
F1, F2
  • F1 Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the Separation Agreement), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement.
  • F2 The stock option is fully vested and exercisable.
Open filing 0001187333-26-000002 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-22RENTON HOLLINGS Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (6,000) — exercise price 76.79
Acquired (A)6,0000—6,000Direct (D) No
F1, F2
  • F1 Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the Separation Agreement), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement.
  • F2 The stock option is fully vested and exercisable.
Open filing 0001187333-26-000002 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-22RENTON HOLLINGS Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (6,000) — exercise price 68.88
Disposed (D)6,0000—6,000Direct (D) No
F1, F2
  • F1 Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the Separation Agreement), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement.
  • F2 The stock option is fully vested and exercisable.
Open filing 0001187333-26-000002 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-22RENTON HOLLINGS Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (6,000) — exercise price 50.47
Acquired (A)6,0000—6,000Direct (D) No
F1, F2
  • F1 Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the Separation Agreement), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement.
  • F2 The stock option is fully vested and exercisable.
Open filing 0001187333-26-000002 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-22RENTON HOLLINGS Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (11,000) — exercise price 16.56
Disposed (D)11,0000—11,000Direct (D) No
F1, F2
  • F1 Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the Separation Agreement), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement.
  • F2 The stock option is fully vested and exercisable.
Open filing 0001187333-26-000002 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-22RENTON HOLLINGS Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (11,000) — exercise price 12.14
Acquired (A)11,0000—11,000Direct (D) No
F1, F2
  • F1 Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the Separation Agreement), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement.
  • F2 The stock option is fully vested and exercisable.
Open filing 0001187333-26-000002 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-22RENTON HOLLINGS Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (11,000) — exercise price 29.70
Disposed (D)11,0000—11,000Direct (D) No
F1, F2
  • F1 Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the Separation Agreement), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement.
  • F2 The stock option is fully vested and exercisable.
Open filing 0001187333-26-000002 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-22RENTON HOLLINGS Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (11,000) — exercise price 21.76
Acquired (A)11,0000—11,000Direct (D) No
F1, F2
  • F1 Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the Separation Agreement), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement.
  • F2 The stock option is fully vested and exercisable.
Open filing 0001187333-26-000002 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-22RENTON HOLLINGS Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (9,200) — exercise price 30.44
Disposed (D)9,2000—9,200Direct (D) No
F1, F2
  • F1 Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the Separation Agreement), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement.
  • F2 The stock option is fully vested and exercisable.
Open filing 0001187333-26-000002 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-22RENTON HOLLINGS Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (9,200) — exercise price 22.13
Acquired (A)9,2000—9,200Direct (D) No
F1, F2
  • F1 Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the Separation Agreement), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement.
  • F2 The stock option is fully vested and exercisable.
Open filing 0001187333-26-000002 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-22RENTON HOLLINGS Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (10,600) — exercise price 23.23
Disposed (D)10,6000—10,600Direct (D) No
F1, F2
  • F1 Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the Separation Agreement), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement.
  • F2 The stock option is fully vested and exercisable.
Open filing 0001187333-26-000002 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-22RENTON HOLLINGS Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (10,600) — exercise price 17.02
Acquired (A)10,6000—10,600Direct (D) No
F1, F2
  • F1 Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the Separation Agreement), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement.
  • F2 The stock option is fully vested and exercisable.
Open filing 0001187333-26-000002 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-22RENTON HOLLINGS Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (16,510) — exercise price 21.19
Disposed (D)16,5100—16,510Direct (D) No
F1, F2
  • F1 Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the Separation Agreement), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement.
  • F2 The stock option is fully vested and exercisable.
Open filing 0001187333-26-000002 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-22RENTON HOLLINGS Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (16,510) — exercise price 15.53
Acquired (A)16,5100—16,510Direct (D) No
F1, F2
  • F1 Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the Separation Agreement), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement.
  • F2 The stock option is fully vested and exercisable.
Open filing 0001187333-26-000002 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-22RENTON HOLLINGS Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (16,510) — exercise price 14.83
Disposed (D)16,5100—16,510Direct (D) No
F1, F2
  • F1 Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the Separation Agreement), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement.
  • F2 The stock option is fully vested and exercisable.
Open filing 0001187333-26-000002 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-22RENTON HOLLINGS Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (16,510) — exercise price 10.87
Acquired (A)16,5100—16,510Direct (D) No
F1, F2
  • F1 Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the Separation Agreement), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement.
  • F2 The stock option is fully vested and exercisable.
Open filing 0001187333-26-000002 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-22RENTON HOLLINGS Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (right to buy) — underlying Common Stock (5,500) — exercise price 43.91
Disposed (D)5,5000—5,500Direct (D) No
F1, F3
  • F1 Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the Separation Agreement), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement.
  • F3 The stock option vests as to 1/12 of the total shares monthly commencing on February 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Open filing 0001187333-26-000002 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-22RENTON HOLLINGS Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (5,500) — exercise price 32.17
Acquired (A)5,5000—5,500Direct (D) No
F1, F3
  • F1 Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the Separation Agreement), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptyBio shares of common stock in an amount determined in accordance with the Separation Agreement.
  • F3 The stock option vests as to 1/12 of the total shares monthly commencing on February 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Open filing 0001187333-26-000002 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-22Faga Daniel Director · Officer: President, CEO
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (16,510) — exercise price 31.12
Disposed (D)11,0000—16,510Direct (D) No
F1, F2
  • F1 Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the Separation Agreement), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement.
  • F2 The stock option is fully vested and exercisable.
Open filing 0001673528-26-000011 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-22Faga Daniel Director · Officer: President, CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (11,000) — exercise price 22.80
Acquired (A)11,0000—11,000Direct (D) No
F1, F2
  • F1 Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the Separation Agreement), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement.
  • F2 The stock option is fully vested and exercisable.
Open filing 0001673528-26-000011 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-22Faga Daniel Director · Officer: President, CEO
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (2,321) — exercise price 31.12
Disposed (D)2,3210—2,321Direct (D) No
F1, F2
  • F1 Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the Separation Agreement), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement.
  • F2 The stock option is fully vested and exercisable.
Open filing 0001673528-26-000011 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-22Faga Daniel Director · Officer: President, CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (2,321) — exercise price 22.80
Acquired (A)2,3210—2,321Direct (D) No
F1, F2
  • F1 Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the Separation Agreement), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement.
  • F2 The stock option is fully vested and exercisable.
Open filing 0001673528-26-000011 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-22Faga Daniel Director · Officer: President, CEO
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (9,200) — exercise price 30.44
Disposed (D)9,2000—9,200Direct (D) No
F1, F2
  • F1 Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the Separation Agreement), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement.
  • F2 The stock option is fully vested and exercisable.
Open filing 0001673528-26-000011 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-22Faga Daniel Director · Officer: President, CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (9,200) — exercise price 22.31
Acquired (A)9,2000—9,200Direct (D) No
F1, F2
  • F1 Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the Separation Agreement), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement.
  • F2 The stock option is fully vested and exercisable.
Open filing 0001673528-26-000011 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-22Faga Daniel Director · Officer: President, CEO
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (194,900) — exercise price 23.23
Disposed (D)194,9000—194,900Direct (D) No
F1, F3
  • F1 Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the Separation Agreement), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement.
  • F3 The stock option vests as to 25% of the total shares on January 6, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Open filing 0001673528-26-000011 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-22Faga Daniel Director · Officer: President, CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (194,900) — exercise price 17.02
Acquired (A)194,9000—194,900Direct (D) No
F1, F3
  • F1 Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the Separation Agreement), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement.
  • F3 The stock option vests as to 25% of the total shares on January 6, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Open filing 0001673528-26-000011 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-22Faga Daniel Director · Officer: President, CEO
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (379,620) — exercise price 21.19
Disposed (D)379,6200—379,620Direct (D) No
F1, F4
  • F1 Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the Separation Agreement), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement.
  • F4 The stock option vests as to 25% of the total shares on January 3, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Open filing 0001673528-26-000011 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-22Faga Daniel Director · Officer: President, CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (379,620) — exercise price 15.53
Acquired (A)379,6200—379,620Direct (D) No
F1, F4
  • F1 Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the Separation Agreement), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement.
  • F4 The stock option vests as to 25% of the total shares on January 3, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Open filing 0001673528-26-000011 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-22Faga Daniel Director · Officer: President, CEO
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (305,500) — exercise price 14.83
Disposed (D)305,5000—305,500Direct (D) No
F1, F5
  • F1 Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the Separation Agreement), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement.
  • F5 The stock option vests as to 25% of the total shares on January 7, 2026, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Open filing 0001673528-26-000011 Read from the filing’s XML Dispute this row
2026-04-20 Filed 2026-04-22Faga Daniel Director · Officer: President, CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (305,500) — exercise price 10.87
Acquired (A)305,5000—305,500Direct (D) No
F1, F5
  • F1 Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the Separation Agreement), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement.
  • F5 The stock option vests as to 25% of the total shares on January 7, 2026, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Open filing 0001673528-26-000011 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,935 filings read, the latest filed 2026-11-20. Prior quarter ending 2026-06-30: 9,178 filings read.

Showing 1–50 of 239

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
EcoR1 Capital, LLC 7,880,094 SH396,053,524 dollarsUnchanged Prior quarter: 7,880,094Open filing 0000935836-26-000577 Filed 2026-11-16 Dispute this row
BlackRock, Inc. Partly reported under another manager1,891,512 SH95,067,394 dollarsHigher by 47,463 Prior quarter: 1,844,049Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row
TANG CAPITAL MANAGEMENT LLC Partly reported under another manager1,474,262 SH74,096,408 dollarsHigher by 143,383 Prior quarter: 1,330,879Open filing 0001214659-26-014410 Filed 2026-11-16 Dispute this row
STATE STREET CORP Partly reported under another manager1,145,901 SH57,592,984 dollarsLower by 140,293 Prior quarter: 1,286,194Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 909,946 SH45,733,886 dollarsHigher by 3,713 Prior quarter: 906,233Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
GOLDMAN SACHS GROUP INC Partly reported under another manager850,343 SH42,738,238 dollarsHigher by 266,273 Prior quarter: 584,070Open filing 0000886982-26-000647 Filed 2026-11-16 Dispute this row
Sanofi 821,917 SH41,309,548 dollarsUnchanged Prior quarter: 821,917Open filing 0001193125-26-448717 Filed 2026-11-05 Dispute this row
D. E. Shaw Co., Inc. Partly reported under another manager819,591 SH41,192,644 dollarsHigher by 279,925 Prior quarter: 539,666Open filing 0001104659-26-128287 Filed 2026-11-16 Dispute this row
MILLENNIUM MANAGEMENT LLC 784,560 SH39,431,986 dollarsLower by 22,756 Prior quarter: 807,316Open filing 0001273087-26-000011 Filed 2026-11-16 Dispute this row
683 Capital Management, LLC Partly reported under another manager740,000 SH37,192,400 dollarsHigher by 80,000 Prior quarter: 660,000Open filing 0001404574-26-000027 Filed 2026-11-16 Dispute this row
CITADEL ADVISORS LLC Partly reported under another manager650,585 SH32,698,402 dollarsHigher by 256,212 Prior quarter: 394,373Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row
GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager639,705 SH32,157,560 dollarsHigher by 1,832 Prior quarter: 637,873Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row
Palo Alto Investors LP 595,264 SH29,917,969 dollarsLower by 8,225 Prior quarter: 603,489Open filing 0002073679-26-000180 Filed 2026-11-16 Dispute this row
Pertento Partners LLP Partly reported under another manager545,003 SH27,391,851 dollarsNot in the prior quarter’s filings read Open filing 0001894571-26-000010 Filed 2026-11-13 Dispute this row
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP Partly reported under another manager495,617 SH24,909,710 dollarsHigher by 6,966 Prior quarter: 488,651Open filing 0001164508-26-000060 Filed 2026-11-13 Dispute this row
FEDERATED HERMES, INC. Partly reported under another manager467,981 SH23,520,725 dollarsHigher by 76,314 Prior quarter: 391,667Open filing 0001623632-26-001675 Filed 2026-11-12 Dispute this row
Apis Capital Advisors, LLC 444,000 SH22,315,440 dollarsLower by 53,000 Prior quarter: 497,000Open filing 0001420506-26-002720 Filed 2026-11-13 Dispute this row
MORGAN STANLEY Partly reported under another manager404,164 SH20,313,306 dollarsHigher by 147,073 Prior quarter: 257,091Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
VANGUARD PORTFOLIO MANAGEMENT LLC 371,647 SH18,678,978 dollarsLower by 156,211 Prior quarter: 527,858Open filing 0002100121-26-001150 Filed 2026-11-13 Dispute this row
JACOBS LEVY EQUITY MANAGEMENT, INC 352,544 SH17,718,861 dollarsHigher by 290,208 Prior quarter: 62,336Open filing 0000884414-26-000004 Filed 2026-11-16 Dispute this row
BANK OF AMERICA CORP /DE/ Partly reported under another manager338,518 SH17,013,915 dollarsLower by 79,294 Prior quarter: 417,812Open filing 0000070858-26-000589 Filed 2026-11-16 Dispute this row
Nuveen, LLC Partly reported under another manager334,941 SH16,834,134 dollarsLower by 85,723 Prior quarter: 420,664Open filing 0000930413-26-003284 Filed 2026-11-10 Dispute this row
Sofinnova Investments, Inc. 330,396 SH16,605,703 dollarsLower by 163,140 Prior quarter: 493,536Open filing 0001104659-26-128032 Filed 2026-11-16 Dispute this row
First Light Asset Management, LLC 328,523 SH16,511,566 dollarsLower by 253,481 Prior quarter: 582,004Open filing 0001999371-26-025524 Filed 2026-11-16 Dispute this row
TWO SIGMA INVESTMENTS, LP 303,984 SH15,278,236 dollarsHigher by 40,989 Prior quarter: 262,995Open filing 0000899140-26-001341 Filed 2026-11-16 Dispute this row
Irenic Capital Management LP 299,215 SH15,038,546 dollarsHigher by 228,768 Prior quarter: 70,447Open filing 0001929389-26-000010 Filed 2026-11-16 Dispute this row
Invesco Ltd. Partly reported under another manager251,325 SH12,631,594 dollarsHigher by 49,269 Prior quarter: 202,056Open filing 0000914208-26-000462 Filed 2026-11-12 Dispute this row
Qube Research Technologies Ltd 232,421 SH11,681,479 dollarsHigher by 3,644 Prior quarter: 228,777Open filing 0001729829-26-000018 Filed 2026-11-13 Dispute this row
FIRST TRUST ADVISORS LP 231,213 SH11,620,765 dollarsLower by 27,776 Prior quarter: 258,989Open filing 0001445546-26-008622 Filed 2026-11-12 Dispute this row
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 217,325 SH10,922,755 dollarsHigher by 15,020 Prior quarter: 202,305Open filing 0000884546-26-000417 Filed 2026-11-16 Dispute this row
HSBC HOLDINGS PLC Partly reported under another manager210,273 SH10,698,690 dollarsLower by 6,676 Prior quarter: 216,949Open filing 0000873630-26-000005 Filed 2026-11-16 Dispute this row
NORTHERN TRUST CORP Partly reported under another manager204,599 SH10,283,146 dollarsHigher by 1,832 Prior quarter: 202,767Open filing 0000073124-26-000067 Filed 2026-11-16 Dispute this row
DIMENSIONAL FUND ADVISORS LP Partly reported under another manager198,008 SH9,951,882 dollarsHigher by 12,564 Prior quarter: 185,444Open filing 0000354204-26-001096 Filed 2026-11-04 Dispute this row
MACKENZIE FINANCIAL CORP 186,688 SH9,382,939 dollarsHigher by 35,709 Prior quarter: 150,979Open filing 0001062993-26-005652 Filed 2026-11-02 Dispute this row
CRCM LP 181,114 SH9,102,790 dollarsNot in the prior quarter’s filings read Open filing 0001483234-26-000007 Filed 2026-11-12 Dispute this row
Diamond Hill Capital Management, LLC (Investment Advisor) 170,112 SH8,549,829 dollarsNot in the prior quarter’s filings read Open filing 0001217541-26-000011 Filed 2026-11-10 Dispute this row
VICTORY CAPITAL MANAGEMENT INC 165,710 SH8,328,584 dollarsLower by 3,517 Prior quarter: 169,227Open filing 0001040188-26-000051 Filed 2026-11-10 Dispute this row
Eversept Partners, LP 154,921 SH7,786,329 dollarsHigher by 84,938 Prior quarter: 69,983Open filing 0001697013-26-000007 Filed 2026-11-16 Dispute this row
VANGUARD FIDUCIARY TRUST CO 150,348 SH7,556,490 dollarsHigher by 3,624 Prior quarter: 146,724Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row
Greenhaven Road Investment Management, L.P. 145,703 SH7,323,033 dollarsLower by 25,356 Prior quarter: 171,059Open filing 0001420506-26-002711 Filed 2026-11-13 Dispute this row
UBS Group AG Partly reported under another manager139,333 SH7,002,876 dollarsLower by 7,499 Prior quarter: 146,832Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
T. Rowe Price Investment Management, Inc. 136,985 SH6,885 dollarsNot in the prior quarter’s filings read Open filing 0001897612-26-000766 Filed 2026-11-16 Dispute this row
Schonfeld Strategic Advisors LLC 110,773 SH5,567,450 dollarsNot in the prior quarter’s filings read Open filing 0001665241-26-000003 Filed 2026-11-16 Dispute this row
Squarepoint Ops LLC Partly reported under another manager109,720 SH5,514,527 dollarsLower by 214,726 Prior quarter: 324,446Open filing 0001642575-26-000012 Filed 2026-11-09 Dispute this row
Ruffer LLP 106,747 SH5,356,239 dollarsNot in the prior quarter’s filings read Open filing 0001426859-26-000014 Filed 2026-11-17 Dispute this row
PRINCIPAL FINANCIAL GROUP INC Partly reported under another manager101,767 SH5,114,809 dollarsNot in the prior quarter’s filings read Open filing 0001126328-26-000225 Filed 2026-11-02 Dispute this row
Connor, Clark Lunn Investment Management Ltd. 94,037 SH4,726,300 dollarsLower by 46,989 Prior quarter: 141,026Open filing 0001596800-26-000018 Filed 2026-11-10 Dispute this row
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. Partly reported under another manager93,732 SH4,710,970 dollarsUnchanged Prior quarter: 93,732Open filing 0000905148-26-004861 Filed 2026-11-16 Dispute this row
Ensign Peak Advisors, Inc 89,512 SH4,498,873 dollarsLower by 17,584 Prior quarter: 107,096Open filing 0001454984-26-000011 Filed 2026-11-12 Dispute this row
CAPITAL FUND MANAGEMENT S.A. Partly reported under another manager85,871 SH4,315,876 dollarsHigher by 46,729 Prior quarter: 39,142Open filing 0001323645-26-000013 Filed 2026-11-13 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • Sixth Street Partners Management Company, L.P. 202,305 SH
  • SG Americas Securities, LLC 66,730 SH
  • RENAISSANCE TECHNOLOGIES LLC 58,300 SH
  • VOLORIDGE INVESTMENT MANAGEMENT, LLC 57,555 SH
  • MARSHALL WACE, LLP 43,822 SH
  • WELLINGTON MANAGEMENT GROUP LLP 41,796 SH
  • Trexquant Investment LP 35,404 SH
  • Tidal Investments LLC 31,270 SH
  • Y-Intercept (Hong Kong) Ltd 18,468 SH
  • Diametric Capital, LP 16,868 SH
  • MILLENNIUM MANAGEMENT LLC 15,000 SH
  • Brevan Howard Capital Management LP 13,329 SH
  • Verition Fund Management LLC 7,500 SH
  • Jupiter Topco LLC 7,464 SH
  • GLENMEDE TRUST CO NA 7,016 SH
  • FMB WEALTH MANAGEMENT 5,592 SH
  • INTECH INVESTMENT MANAGEMENT LLC 5,397 SH
  • Hillsdale Investment Management Inc. 5,150 SH
  • Ancora Advisors LLC 5,000 SH
  • Marex Group Ltd 4,962 SH
  • Susquehanna Portfolio Strategies, LLC 4,882 SH
  • Moran Wealth Management, LLC 3,981 SH
  • ADAR1 Capital Management, LLC 3,698 SH
  • nVerses Capital, LLC 3,557 SH
  • ProShare Advisors LLC 3,544 SH
  • Verdad Advisers, LP 3,498 SH
  • MANGROVE PARTNERS IM, LLC 3,475 SH
  • E Fund Management Co., Ltd. 3,083 SH
  • Kestra Advisory Services, LLC 3,066 SH
  • State of Wyoming 2,347 SH
  • MERCER GLOBAL ADVISORS INC /ADV 1,727 SH
  • SIMPLEX TRADING, LLC 900 SH
  • Persistent Asset Partners Ltd 575 SH
  • Pacer Advisors, Inc. 365 SH
  • Quantbot Technologies LP 175 SH
  • Integrated Wealth Concepts LLC 70 SH
  • HOLLENCREST CAPITAL MANAGEMENT 50 SH
  • Optiver Holding B.V. 45 SH
  • Decker Retirement Planning Inc. 43 SH
  • Global Retirement Partners, LLC 36 SH
  • Stone House Investment Management, LLC 12 SH
  • NATIONAL BANK OF CANADA /FI/ 8 SH
  • Avion Wealth 7 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • Reports for quarters ending before 2013-06-30 were filed as plain text and are not read.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
EcoR1 Capital, LLC Common Stock27.88,254,67411/16/2026 Filed 2026-11-18SCHEDULE 13D/AAmendment 4Open filing 0000935836-26-000634 Dispute this row
Oleg Nodelman Common Stock27.88,254,67411/16/2026 Filed 2026-11-18SCHEDULE 13D/AAmendment 4Open filing 0000935836-26-000634 Dispute this row
EcoR1 Capital Fund Qualified, L.P. Common Stock25.77,642,93711/16/2026 Filed 2026-11-18SCHEDULE 13D/AAmendment 4Open filing 0000935836-26-000634 Dispute this row
Sirenia Capital Management LP Common Stock, par value $0.001 per share3.1924,640.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 2Open filing 0000919574-26-007951 Dispute this row
Alex Silverstein Common Stock, par value $0.001 per share3.1924,640.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 2Open filing 0000919574-26-007951 Dispute this row
Sirenia Capital Management LP Common Stock, par value $0.001 per share5.01,491,959.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0000919574-26-005200 Dispute this row
Alex Silverstein Common Stock, par value $0.001 per share5.01,491,959.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0000919574-26-005200 Dispute this row
Point72 Asset Management, L.P. Common Stock, par value $0.001 per share0.255,303.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 2Open filing 0000919574-26-003483 Dispute this row
Point72 Capital Advisors, Inc. Common Stock, par value $0.001 per share0.255,303.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 2Open filing 0000919574-26-003483 Dispute this row
Steven A. Cohen Common Stock, par value $0.001 per share0.255,303.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 2Open filing 0000919574-26-003483 Dispute this row
Sirenia Capital Management LP Common Stock, par value $0.001 per share6.71,920,402.0003/31/2026 Filed 2026-05-15SCHEDULE 13GOpen filing 0000919574-26-003215 Dispute this row
Alex Silverstein Common Stock, par value $0.001 per share6.71,920,402.0003/31/2026 Filed 2026-05-15SCHEDULE 13GOpen filing 0000919574-26-003215 Dispute this row
The Vanguard Group Common Stock0003/13/2026 Filed 2026-03-26SCHEDULE 13G/AAmendment 1Open filing 0000102909-26-000635 Dispute this row
Morgan Stanley Common Stock3.61,006,06312/31/2025 Filed 2026-02-11SCHEDULE 13G/AAmendment 1Open filing 0000895421-26-000034 Dispute this row
Morgan Stanley Capital Services LLC Common Stock3.2879,35112/31/2025 Filed 2026-02-11SCHEDULE 13G/AAmendment 1Open filing 0000895421-26-000034 Dispute this row
Millennium Management LLC Common Stock, par value $0.001 per share2.9813,571.0012/31/2025 Filed 2026-01-16SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-004557 Dispute this row
Millennium Group Management LLC Common Stock, par value $0.001 per share2.9813,571.0012/31/2025 Filed 2026-01-16SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-004557 Dispute this row
Israel A. Englander Common Stock, par value $0.001 per share2.9813,571.0012/31/2025 Filed 2026-01-16SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-004557 Dispute this row
First Light Asset Management, LLC Common Stock, $0.01 par value2.78770,568.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 2Open filing 0001999371-25-017924 Dispute this row
Mathew P. Arens Common Stock, $0.01 par value3.12864,618.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 2Open filing 0001999371-25-017924 Dispute this row
THE GOLDMAN SACHS GROUP, INC. Common Stock, par value $0.001 per share4.51,251,294.7909/30/2025 Filed 2025-11-12SCHEDULE 13G/AAmendment 1Open filing 0000886982-25-001442 Dispute this row
GOLDMAN SACHS CO. LLC Common Stock, par value $0.001 per share4.51,251,294.7909/30/2025 Filed 2025-11-12SCHEDULE 13G/AAmendment 1Open filing 0000886982-25-001442 Dispute this row
Millennium Management LLC Common Stock, par value $0.001 per share5.11,426,893.0009/16/2025 Filed 2025-09-23SCHEDULE 13GOpen filing 0001104659-25-092506 Dispute this row
Millennium Group Management LLC Common Stock, par value $0.001 per share5.11,426,893.0009/16/2025 Filed 2025-09-23SCHEDULE 13GOpen filing 0001104659-25-092506 Dispute this row
Israel A. Englander Common Stock, par value $0.001 per share5.11,426,893.0009/16/2025 Filed 2025-09-23SCHEDULE 13GOpen filing 0001104659-25-092506 Dispute this row
First Light Asset Management, LLC Common Stock, $0.01 par value7.262,133,903.0007/31/2025 Filed 2025-08-07SCHEDULE 13G/AAmendment 1Open filing 0001999371-25-010859 Dispute this row
Mathew P. Arens Common Stock, $0.01 par value7.712,265,903.0007/31/2025 Filed 2025-08-07SCHEDULE 13G/AAmendment 1Open filing 0001999371-25-010859 Dispute this row
Morgan Stanley Common Stock6.31,845,00206/30/2025 Filed 2025-08-05SCHEDULE 13GOpen filing 0000895421-25-000442 Dispute this row
Morgan Stanley Capital Services LLC Common Stock5.21,525,50206/30/2025 Filed 2025-08-05SCHEDULE 13GOpen filing 0000895421-25-000442 Dispute this row
The Vanguard Group Common Stock5.231,537,55006/30/2025 Filed 2025-07-29SCHEDULE 13GOpen filing 0000932471-25-000804 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,694,798 filings read, dated 2004-06-14 to 2026-11-20: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
2015111,180
2016222,642
2017222,009
2018223,345
2019216,482
2020226,343
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026263,828

Filings made before the SEC required XML are listed, not extracted.

Back to ANAPTYSBIO, INC.